3337 Safety and effectiveness analysis of V600 BRAF-mutated metastatic melanoma (MM) patients (pts) from the dabrafenib (D) plus trametinib (T) named patient programme (NPP) - DESCRIBE II study — Victoria Atkinson (2015)

Article2017

Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma

Alexander M. Menzies, Maria Gonzalez, Alex Guminski, Omgo E. Nieweg, Kerwin F. Shannon, John F. Thompson, Richard Kefford, Sydney Ch’ng, Jonathan R. Stretch, Andrew J. Spillane, J. Lee, H. Lee, Rony Kapoor, Louise Emmett, Helen Rizos, Robyn P.M. Saw, Richard A Scolyer, Georgina V. Long

Article2016

Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.

Robyn P.M. Saw, Alexander M. Menzies, Alexander Guminski, Omgo E. Nieweg, Kerwin F. Shannon, Maria Gonzalez, Sydney Ch’ng, Richard Kefford, John F. Thompson, Jonathan R. Stretch, Andrew J. Spillane, Richard A Scolyer, Georgina V. Long

Article2017

A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)

Maria Gonzalez, Alexander M. Menzies, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Julie R. Howle, Omgo E. Nieweg, Kerwin F. Shannon, Sydney Ch’ng, Jonathan R. Stretch, Matteo S. Carlino, Alexander Guminski, Louise Emmett, Helen Rizos, Richard A Scolyer, Georgina V. Long

Preprint2023

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

James S. Wilmott, Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M. Ferguson, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Lisa H. Butterfield, Richard A Scolyer, John M. Kirkwood, Georgina V. Long, Michael A. Davies

Preprint2023

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

James S. Wilmott, Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M. Ferguson, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Lisa H. Butterfield, Richard A Scolyer, John M. Kirkwood, Georgina V. Long, Michael A. Davies

3337 Safety and effectiveness analysis of V600 BRAF-mutated metastatic melanoma (MM) patients (pts) from the dabrafenib (D) plus trametinib (T) named patient programme (NPP) - DESCRIBE II study

Discussion(0)

Related publications

Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma

Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.

A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases